Sylvia Pruetting

Sylvia Pruetting currently serves as the Head of CMC Regulatory Affairs at Immunic Therapeutics since July 2024. Prior experience includes roles as Head of Regulatory Affairs CMC Drug Product and Senior Manager Regulatory Affairs CMC Drug Product and Device at Formycon AG, where responsibilities encompassed the establishment and development of CMC modules for sterile ophthalmic products and regulatory support for biosimilar projects. Additionally, Pruetting held the position of MA Regulatory Affairs at Vetter-Pharma Fertigung GmbH & Co. KG, focusing on regulatory submissions for sterile manufactured products. Previous roles include Manager of Quality Assurance and Research Scientist at 4SC AG, with foundational work in electrophysiology during postdoctoral fellowships at 4SC AG and the University of Ulm. Education includes a Dr. biol. hum. in Electrophysiology from Ulm University and a Staatsexamen in Lebensmittelchemie from Goethe University Frankfurt.